A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)
Condition(s):B-cell Acute Lymphoblastic LeukemiaLast Updated:March 8, 2024Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):B-cell Acute Lymphoblastic LeukemiaLast Updated:March 8, 2024Not yet recruiting
Condition(s):B-ALLLast Updated:April 18, 2023Recruiting
Condition(s):CD19+ Relapse/Refractory B-ALLLast Updated:March 8, 2022Recruiting
Condition(s):B-Cell Acute Lymphoblastic LeukemiaLast Updated:March 8, 2022Recruiting
Condition(s):B Acute Lymphoblastic Leukemia; Ph-Negative ALL; High Risk Acute Lymphoblastic LeukemiaLast Updated:October 17, 2023Not yet recruiting
Condition(s):B Acute Lymphoblastic LeukemiaLast Updated:March 7, 2024Completed
Condition(s):B-cell Acute Lymphoblastic Leukemia; B-ALLLast Updated:November 30, 2022Withdrawn
Condition(s):Acute Lymphoid LeukemiaLast Updated:August 9, 2023Active, not recruiting
Condition(s):B-cell Acute Lymphoblastic Leukemia; B-ALLLast Updated:December 8, 2022Recruiting
Condition(s):CD22+ Relapsed/Refractory B-ALLLast Updated:January 19, 2017Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.